TIAA CREF Investment Management LLC Buys 13,438 Shares of Insmed, Inc. (INSM)


TIAA CREF Investment Management LLC boosted its stake in shares of Insmed, Inc. (NASDAQ:INSM) by 5.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 244,624 shares of the biopharmaceutical company’s stock after acquiring an additional 13,438 shares during the quarter. TIAA CREF Investment Management LLC’s holdings in Insmed were worth $7,627,000 as of its most recent filing with the Securities and Exchange Commission.


A number of other institutional investors also recently bought and sold shares of INSM. American International Group Inc. lifted its holdings in shares of Insmed by 4.6% in the 4th quarter. American International Group Inc. now owns 51,539 shares of the biopharmaceutical company’s stock valued at $1,607,000 after buying an additional 2,255 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Insmed by 137.4% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,662 shares of the biopharmaceutical company’s stock valued at $145,000 after buying an additional 2,698 shares during the period. Swiss National Bank lifted its holdings in shares of Insmed by 2.4% in the 4th quarter. Swiss National Bank now owns 119,600 shares of the biopharmaceutical company’s stock valued at $3,729,000 after buying an additional 2,800 shares during the period. QS Investors LLC lifted its holdings in shares of Insmed by 5.2% in the 4th quarter. QS Investors LLC now owns 75,620 shares of the biopharmaceutical company’s stock valued at $2,358,000 after buying an additional 3,771 shares during the period. Finally, California Public Employees Retirement System lifted its holdings in shares of Insmed by 4.8% in the 4th quarter. California Public Employees Retirement System now owns 86,600 shares of the biopharmaceutical company’s stock valued at $2,700,000 after buying an additional 4,000 shares during the period. 99.08% of the stock is owned by institutional investors.


How to Become a New Pot Stock Millionaire

Several analysts have recently commented on the company. ValuEngine raised Insmed from a “hold” rating to a “buy” rating in a report on Monday. BidaskClub raised Insmed from a “sell” rating to a “hold” rating in a report on Wednesday. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price objective on shares of Insmed in a research note on Thursday, January 4th. Robert W. Baird reaffirmed a “positive” rating and issued a $42.00 price objective (up from $32.00) on shares of Insmed in a research note on Thursday, January 4th. Finally, Zacks Investment Research downgraded Insmed from a “buy” rating to a “hold” rating in a research note on Friday, January 12th. One analyst has rated the stock with a sell rating, three have issued a hold rating and eight have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $36.90.


NASDAQ INSM opened at $23.85 on Friday. Insmed, Inc. has a 1-year low of $11.49 and a 1-year high of $33.94. The company has a market capitalization of $1,736.28, a P/E ratio of -8.25 and a beta of 1.11. The company has a quick ratio of 8.72, a current ratio of 8.72 and a debt-to-equity ratio of 0.15.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Friday, February 23rd. The biopharmaceutical company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.18). equities research analysts expect that Insmed, Inc. will post -3.8 EPS for the current fiscal year.


TRADEMARK VIOLATION WARNING: “TIAA CREF Investment Management LLC Buys 13,438 Shares of Insmed, Inc. (INSM)” was first posted by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at www.tickerreport.com/banking-finance/3353518/tiaa-cref-investment-management-llc-buys-13438-shares-of-insmed-inc-insm.html.

Insmed Profile


Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).

Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed, Inc. (NASDAQ:INSM).

Institutional Ownership by Quarter for Insmed (NASDAQ:INSM)